No new evidence identified to support changes to the 2016 recommendation against routine serologic screening for genital herpes
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, Aug. 16, 2022 (HealthDay News) -- The U.S. Preventive Services Task Force (USPSTF) did not find new evidence that could result in a change to the 2016 recommendation on screening for genital herpes and consequently continues to recommend against routine serologic screening. This conclusion forms the basis of a draft recommendation statement published online Aug. 16.
Gary N. Asher, M.D., M.P.H., from RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center in Research Triangle Park, and colleagues dually reviewed 3,119 abstracts and 64 full-text articles against a priori eligibility criteria to identify evidence that could result in a change in the 2016 USPSTF D recommendation for herpes simplex virus 2 (HSV-2) screening. The researchers did not identify any new eligible studies on the benefits or harms of HSV-2 serologic screening, accuracy of available HSV-2 serologic tests, or preventive interventions that could be used in asymptomatic individuals who are seropositive for HSV-2 to reduce morbidity and transmission of genital herpes. Foundational evidence that informed the 2016 recommendation indicated a high-rate of false-positive test results and potential psychosocial harms associated with serologic screening for genital herpes.
Based on these findings, the USPSTF continues to recommend against routine serologic screening for genital herpes simplex virus infection in asymptomatic adolescents and adults, including pregnant persons (D recommendation).
The draft recommendation statement and draft evidence review have been published for public comment. Comments can be submitted from Aug. 16 to Sept. 12, 2022.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on September 21, 2022
Read this Next
Other Trending Articles